"To the best of our knowledge, there are very few examples where a continuous-flow bromination has been developed that includes an in-line purification before telescoping into a subsequent reactor..."I llooked at the various syntheses and it appears that with the 'moonrock' MDMA, halogenation of the aromatic was the most commonly observed impurity.
But in all fairness, 'moonrock' does essentially mean nobody in the chain from producer to consumer can cut the stuff. In the 80s pill presses were hard to obtain and costly so those who made Doves (or whatever your favouroite was) had invested a considerable ammount in branding their product to keep up the value.
Then idiots would buy good pills, crush them, add a cut or just repress with less in each pill. So nobody really knew what they were getting and value collapsed. So someone has VERY cleverly solved this issue for now at least. SOMEONE will figure out how to adulterate moonrock...
Also please note, I understand this is norket via a-bromo (ketone) compounds or even potentially, B or y if you dig more. However, Conversion and yield were determined by
"1H NMR using 1,3,5-trimethoxybenzene as an internal standard Isolated yield." ...1,2,3-trimethoxybenzene to 1,3,5-trimethoxybenzene involves "Friedel-Crafts acylation" followed by a decarboxylation step then forward yields... well that isn't important here,
The importance here is for someone /anyone who doesn't know chemistry, and how it is related is that most reactions can sub bromo for iodo, etc. etc.
Anyways take a look at for reference
. _________ ________ proceeds via tricarbonyl(h6-1,2,3-trimethoxybenzene)chromium complex. Treatment of tricarbonyl(h6-1,2,3-trimethoxybenzene)chromium complex 1 with acetonitrile carbanion in THF and then with iodine followed by reduction of the nitrile function gives mescaline. Deprotonation of complex 1 at the C5 carbon with LiTMP followed by chlorination, bromation or iodation gives 5-chloro, 5-bromo or 5-iodo complexes, useful synthons in organic synthesis for the preparation of 1,2,3-trimethoxy-5-substituted derivatives, precursors of natural products. Hydrogenation of the nitrile 5 using a literature procedure [2g] gave me_ _ _ _ _ _ _ in 80% yield and in 66% overall yield starting from 1,2,3-trimethoxybenzene
Continuous processing is becoming increasingly attractive for the manufacture of medicines because it offers opportunities for faster process development and safer handling of hazardous reagents. (1) Over the past two decades, continuous-flow chemistry has become commonplace in both academia and industry and nowadays it pervades the whole process of research, from reaction discovery and optimization to scale-up and production of fine chemicals and active pharmaceutical ingredients. (2) The increasing interest in this field stems from the many advantages that synthesis in-flow can offer. Specifically, processes can often be made safer, greener, and more efficient when performed in continuous flow. These benefits are particularly apparent when working with hazardous materials, where the scalability of a process in a batch format can be problematic. (3,4) Flow chemistry also offers flexibility in reconfiguring reactors to adapt to changing manufacturing requirements. This is particularly useful in the context of personalized medicine, which leads to the production of a larger number of compounds but in relatively small amounts. In this paper, we demonstrate how flow chemistry can simplify the synthesis of norketamine (5), a pharmaceutically relevant metabolite of the antidepressant, ketamine (4). We take advantage of flow chemistry to minimize the risks of handling toxic reagents such as ammonia and molecular bromine on a kilo scale. In our experience, we found that the resultant crude mixture remained considerably colored following this protocol (an indication of bromine and/or its derivatives) and we were keen to develop a procedure that efficiently removed these contaminants. As such, several aqueous quench solutions were trialed."
A three-stage continuous-flow process for the synthesis of norketamine (5) is reported. Initially, α-bromination of the key precursor 1 was achieved with quantitative conversion using a CSTR that allowed the safe removal and quenching of the hydrogen bromide by-product. This process was demonstrated on a 0.89 kg/day scale. Next, the subsequent imination process was achieved in excellent yield, representing a rare example of the use of liquid ammonia in a continuous-flow reactor. It was then demonstrated that these processes can be linked via an in-line quench and purification with a liquid–liquid membrane separator. Finally, the last step in the synthesis of norketamine (5) was achieved on a 1.4 kg scale via the thermal rearrangement of the α-hydroxy imine 3 in a commercially available tubular flow reactor.
The product was not isolated but instead N-Boc protected for use in subsequent steps
See
Organic Process Research & Development
Cite this: Org. Process Res. Dev. 2022, 26, 4, 1145–1151
Copyright © 2022 American Chemical Society. This publication is licensed under
Published March 26, 2022 for more on telescopic (α-bromoketone)
At least how I read it.
Last edited:
